Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
61-80 of 1,782 trials

Cirrhosis and Ascites: Personalized Human Albumin Treatment

We are studying a tailored approach to human albumin therapy for patients with liver cirrhosis and fluid buildup. The goal is to identify who may respond best to this treatment.

Liver Cirrhosis>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesCost ReimbursementHepatologyInternal Medicine

Multiple Sclerosis: Rituximab vs. Ocrelizumab Study

We are comparing two treatments for relapsing-remitting multiple sclerosis to see if rituximab is as effective as ocrelizumab in preventing disease activity. This study also examines patient quality of life and other important factors.

Multiple Sclerosis1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesNeurology

COPD: Eosinophil-Guided Inhaled Corticosteroid Reduction

We are studying whether adjusting inhaled corticosteroid treatment based on eosinophil levels helps patients with severe COPD. We also want to see if low-dose Azithromycin can reduce hospital visits and improve overall health.

Chronic Obstructive Pulmonary Disease (COPD)>2 yearsMonitoring phase (IV)Standard MedicinesInternal MedicinePulmonology

Acute Lymphoblastic Leukaemia: ALLTogether Treatment Study

We are studying new treatment options for children and young adults aged 0-45 with newly diagnosed acute lymphoblastic leukaemia. The goal is to improve survival and quality of life through various interventions.

Acute Lymphoblastic Leukaemia>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

ANCA-Associated Vasculitis: Pioglitazone Treatment

We are studying whether adding pioglitazone to standard treatments can improve kidney function in patients with ANCA-associated vasculitis. The trial also looks at quality of life and potential side effects.

ANCA-associated Vasculitis>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteNephrologyRheumatology

Migraine Prevention: Atogepant for Kids

We are studying the long-term safety and tolerability of atogepant in children and teens aged 6 to 17 with migraines. This research aims to ensure the treatment is safe for young patients.

Migraine1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Episodic Migraine: Atogepant for Kids and Teens

We are studying the safety and effectiveness of Atogepant tablets for children and teens aged 6 to 17 with episodic migraines. This trial compares the medication to a placebo to see if it helps reduce migraine symptoms.

Episodic Migraine3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Arthritis from Cancer Immunotherapy: Tocilizumab Study

We are investigating whether adding tocilizumab to short-term glucocorticoids helps people with arthritis caused by cancer immunotherapy more than glucocorticoids alone. This study aims to improve arthritis control and patient outcomes.

Arthritis from Cancer TreatmentEfficacy phase (II)No PlaceboStandard MedicinesOncologyRheumatology

Migraine Relief: High-Flow Oxygen Therapy

We are studying whether high-flow oxygen therapy can help relieve migraine attacks in the emergency department. The trial also looks at its effects on related symptoms and overall patient experience.

Common Migraine1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNeurology

Primary Membranous Nephropathy: Zanubrutinib vs. Tacrolimus

We are studying whether zanubrutinib can reduce protein levels in urine and lead to remission in patients with primary membranous nephropathy compared to tacrolimus. This trial aims to evaluate the safety and effectiveness of both treatments.

Primary Membranous Nephropathy1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNephrology

Sedation in Older Critically Ill Patients: Dexmedetomidine vs. Placebo

We are studying whether early sedation with dexmedetomidine improves survival and health outcomes in patients aged 65 and older on ventilators. This trial aims to build on previous findings about sedation in critically ill patients.

Critically Ill PatientsMonitoring phase (IV)Standard MedicinesInternal MedicineOtolaryngologyPsychiatryPulmonology

Diffuse Large B-Cell Lymphoma: Acalabrutinib with R-miniCHOP

We are studying whether adding acalabrutinib to a reduced chemotherapy regimen helps older adults with untreated diffuse large B-cell lymphoma live longer and have better treatment responses. This trial is for those over 60 or 80 years who cannot receive full-dose chemotherapy.

High-Grade B-Cell Lymphoma>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Pembrolizumab for Children with Advanced Melanoma and Solid Tumors

We are studying the safety and effectiveness of pembrolizumab in children with advanced melanoma or certain relapsed solid tumors and lymphoma. This trial aims to understand how well this treatment works and its potential side effects.

Advanced Melanoma and Related CancersSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncologyPediatrics

Brexucabtagene Autoleucel for Rare B-cell Malignancies

We are studying a new treatment for adults with relapsed or refractory Richter Transformation of B-cell malignancies. The goal is to see if it improves response rates and overall survival compared to existing options.

Relapsed/Refractory Richter Transformation1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Sodium Bicarbonate for Cardiac Arrest Treatment

We are studying whether sodium bicarbonate can help patients regain heart function during in-hospital cardiac arrest. The trial also looks at its effects on survival and neurological outcomes after 30 days.

In-Hospital Cardiac Arrest1-2 yearsMonitoring phase (IV)Standard MedicinesCardiology

Multiple Sclerosis: Ozanimod vs. Fingolimod

We are studying whether the new medication ozanimod is more effective and safe than fingolimod for children and adolescents with relapsing remitting multiple sclerosis. This trial will also assess how the body handles ozanimod.

Relapsing-Remitting Multiple SclerosisConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurology

Rituximab for Progressive Interstitial Lung Disease

We are studying whether rituximab can improve lung function in patients with progressive interstitial lung disease. This trial compares its effects to a placebo to assess safety and quality of life.

Interstitial Lung Disease>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsStandard MedicinesInternal MedicinePulmonology

Axial Spondyloarthritis: Filgotinib Study

We are testing the medication filgotinib in adults with active axial spondyloarthritis to see if it improves symptoms and physical function compared to a placebo. The study also looks at the safety of this treatment.

Axial Spondyloarthritis>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Acute Myeloid Leukemia: Oral-Azacitidine with Gilteritinib

We are studying a new combination treatment for adults with relapsed or refractory FLT3-mutated acute myeloid leukemia. The goal is to see if this approach improves remission rates and safety compared to current options.

Acute Myeloid Leukaemia>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

COVID-19 Treatment: Antiviral Therapy for Immunocompromised Patients

We are studying a combination of antiviral medications to see if it helps immunocompromised patients recover from COVID-19 more effectively. The goal is to improve viral clearance and reduce symptoms compared to standard treatments.

Covid-193-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine